[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].

Introduction. The benefit of tyrosine kinase inhibitors for patients with an EGFR wild-type non-small cell lung cancer (NSCLC) remains controversial. Methods. The survival of patients with an EGFR wild-type NSCLC who received second-or third-line erlotinib treatment was assessed using real-life data that had been collected in a prospective, national, multicenter, non-interventional cohort study. Results. Data from 274 patients were analysed, 185 (68%) treated with erlotinib and 89 (32%) treated with supportive care only. The median overall survival was 4.2 months (95% CI [3.5; 5.4]) with erlotinib, and 1.3 months (95% CI [1.0; 1.8]) with supportive care. Survival rate at 3, 6, and 12 months was 62%, 37%, and 17%, respectively, with erlotinib, versus 20%, 8%, et 3%, with exclusive supportive care. Significant predictive factors for longer overall survival were the presence of adenocarcinoma, and use of 1st line chemotherapy including either taxanes, pemetrexed or vinorelbine (P < 0.05). Conclusion. Erlotinib remains a valuable therapeutic option to treat inoperable locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen in fragile patients who are not eligible for chemotherapy. (C) 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.